Overview

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Status:
RECRUITING

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

lenvatinib
tislelizumab